Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos - Endpoints News
Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and adding to Novartis' cardiovascular pipeline.
By:Kyle LaHucik
Source:Endpoints News
Published:
Related News
Alibaba-backed startup Moonshot AI's valuation is up $500 million, sources say, after its rivals IPO in Hong Kong - CNBC
Investors are valuing the startup at $4.8 billion as it is about to close another funding round, according to two people familiar with the matter.
CNBC•Evelyn Cheng
Stellantis stock off 43% as Jeep maker turns five, executes turnaround - CNBC
Stellantis shares were largely up – as high as 93% in March 2024 – until reporting troubling financial results that year amid cost-cutting efforts and EVs.
CNBC•Michael Wayland
10 things I learned from burning myself out with AI coding agents - Ars Technica
Opinion: As software power tools, AI agents may make people busier than ever before.
Ars Technica•Benj Edwards